Drug intelligence / Profile preview

11C-HY-2-15

Development stage: Phase 1
Lead developer: University of Pennsylvania
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

11C-HY-2-15 is a diagnostic radiopharmaceutical developed for PET imaging of alpha-synuclein fibrils in the brain. It's designed to quantify abnormal alpha-synuclein deposits in neurodegenerative diseases such as Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). The radiotracer is being investigated to compare uptake patterns between patients with these conditions and non-Parkinsonism volunteers.

Other names: [11C]M50311C-M503 PET

Targets

Tau aggregates (Microtubule-associated protein tau (pathological form))aggregated α-syn (Alpha-synuclein (α-syn))

Beyond the preview

Go deeper on 11C-HY-2-15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 11C-HY-2-15.

Explore the full profile